CNBC
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Saturday, July 11, 2026
Vivani Medical is developing a subcutaneous implant containing semaglutide, the active ingredient in Novo Nordisk's Wegovy obesity treatment and Ozempic diabetes medication. The implant is designed to deliver the drug over an extended period. Novo Nordisk currently markets semaglutide as an injectable medication requiring regular self-administration.